Daklinza Side Effects Linked to Cases of Liver Failure
Recent warnings issued by Japanese health regulators suggest that side effects of the recently introduced hepatitis C drug Daklinza may increase the risk liver failure.
Daklinza (daclatasvir) is a Bristol-Myers Squibb drug that was just approved in the United States in July, for treatment of patients with chronic hepatitis C genotype 3. It is a 12-week course of once-per-day oral tables that are believed to have a 96% chance of successfully curing patients who have not experienced cirrhosis.
The regimen costs $63,000 for a 12 week treatment program, and it must be used with Sovaldi in the U.S., a Gilead hepatitis drug that costs $84,000 for 12 weeks. The high cost of $1,750 per day for the two pills, has drawn fire from critics as being excessive, so the potential safety concerns raise further concerns.
Did You Know?
Ticketmaster Data Breach Impacts Millions of Customers
A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.
Learn MoreThis week, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) ordered new label warnings (PDF, translation required) on Daklinza and another similar drug that is not approved in the United States, Sunvepra (asunaprevir). The warnings indicate that patients may experience a sudden decrease in liver function that could result in liver failure from Daklinza or Sunvepra.
Daklinza has been available in Japan longer than the U.S., and the PMDA warns that those treated with the drug have reported decreased albumin levels, prolonged prothrombin time, hepatic encephalopathy and hepatic failure.
The Japanese regulators have received at least 37 reports of decreased liver function from Daklinza and Sunvepra users, including one death report. While liver problems are frequently associated with hepatitis C, Japanese investigators have been unable to rule out a causal relationship between the drugs and the liver problems in 21 of those cases.
The Phase III study provided by Bristol-Myers Squibb to the FDA, known as ALLY-3, looked at only 152 patients with chronic hepatitis C genotype 3 and found no treatment-related serious adverse events, and no discontinuations due to adverse events. Bristol-Myers Squibb has indicated that the most frequent side effects of Daklinza were headache, fatigue, nausea and diarrhea.
2 Comments
GregSeptember 21, 2017 at 1:40 pm
Danielle, I am sorry to learn about your side effects. A few years ago I was prescribed Daklinza and Sovaldi but I never went ahead with the treatment therapy because I recall reading about Bristol Myers Squibb and the failed drug it also created for HCV (BMS-986094) which killed a 25-year-old clinical trial patient and caused heart and kidney problems in others. This confirms my next step in not [Show More]Danielle, I am sorry to learn about your side effects. A few years ago I was prescribed Daklinza and Sovaldi but I never went ahead with the treatment therapy because I recall reading about Bristol Myers Squibb and the failed drug it also created for HCV (BMS-986094) which killed a 25-year-old clinical trial patient and caused heart and kidney problems in others. This confirms my next step in not pursuing treatment from BMS. Thank you. And again, my apologies.
DanielleDecember 31, 2016 at 4:48 pm
Prior to hcv treatment with sovaldi/ daklinza I was healthy. After treatment I'm left with kidney damage. I was never told of all the side effects of the wonder drug.